Attached files
| file | filename |
|---|---|
| EX-99 - EXHIBIT 99 PRESS RELEASE DATED MAY 8, 2020, ISSUED BY THERAPEUTIC SOLUTIONS INTE - THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. | f8k060920_ex99.htm |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 9, 2020
THERAPEUTIC SOLUTONS INTERNATIONAL, INC. |
(Exact Name of Registrant as Specified in its Charter) |
Nevada |
| 000-54554 |
| 45-1226465 |
(State or other jurisdiction of incorporation or organization) |
| (Commission File Number) |
| (I.R.S. Employer Identification Number) |
4093 Oceanside Boulevard, Suite B |
Oceanside, California 92056 |
(Address of Principal Executive Offices and Zip Code) |
|
(760) 295-7208 |
(Issuer's telephone number) |
|
Not Applicable |
(Former Name or Former Address, if Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On May 8, 2020, Therapeutic Solutions International, Inc. released the following headline in a press release “Therapeutic Solutions International Initiates 500 Volunteer COVID-19 Prevention Clinical Trial Using QuadraMune™”. The new clinical trial has been granted ClinicalTrials.gov Identifier: NCT04421391 on Friday June 5th. On June 9, 2020 the Protocol Registration and Results System (PRS) has posted our registration and is available on the Federal Clinical Trial registry at this link https://clinicaltrials.gov/ct2/show/NCT04421391
Item 9.01 Financial Statements and Exhibits.
Exhibit Index
(99)Press release dated May 8, 2020, issued by Therapeutic Solutions International, Inc.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 9, 2020
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.
By: /s/ Timothy Dixon
Timothy Dixon
Chief Executive Officer